Abstract
Current Pharmaceutical Design
Title: Editorial [Hot Topic: Novel Anti-Cancer Drugs and Therapeutic Approaches (Executive Editor: E. Bergmann-Leitner)]
Volume: 12 Issue: 3
Author(s): E. Bergmann-Leitner
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Bergmann-Leitner E., Editorial [Hot Topic: Novel Anti-Cancer Drugs and Therapeutic Approaches (Executive Editor: E. Bergmann-Leitner)], Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201938
DOI https://dx.doi.org/10.2174/138161206775201938 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Severe Adenovirus Pneumonia Followed by Bacterial Septicaemia: Relevance of Co-Infections in Allogeneic Hematopoietic Stem Cell Transplantation
Infectious Disorders - Drug Targets Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders
Current Drug Targets - Cardiovascular & Hematological Disorders Carbon Monoxide in Acute Lung Injury
Current Pharmaceutical Biotechnology Epidemiology and Prevention of Viral Infections in Patients with Hematologic Malignancies
Infectious Disorders - Drug Targets Aberrant Regulation of Translation Initiation in Tumorigenesis
Current Molecular Medicine Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Treatment of Inflammatory and Paraproteinemic Neuropathies
Current Drug Targets - Immune, Endocrine & Metabolic Disorders An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Prevention of Colitis-associated Cancer: Natural Compounds that Target the IL-6 Soluble Receptor
Anti-Cancer Agents in Medicinal Chemistry